Mineralocorticoid receptor blockade in chronic kidney disease

Blood Purification

Volumn 33, Issue 1-3, 2012, Pages 119-124

  Bomback, Andrew S ^a   Klemmer, Philip J ^b  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Aldosterone; Aldosterone breakthrough; Bioimpedance; Chronic kidney disease; Extracellular volume; Hyperkalemia; Mineralocorticoid blockade; Proteinuria; Tissue inflammation

Indexed keywords

ALDOSTERONE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; FUROSEMIDE; GLUCOCORTICOID RECEPTOR ANTAGONIST; LISINOPRIL; LOSARTAN; MINERALOCORTICOID RECEPTOR BLOCKER; PLACEBO; SPIRONOLACTONE; TRICHLORMETHIAZIDE; UNCLASSIFIED DRUG;

ALDOSTERONE BLOOD LEVEL; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG SAFETY; EXTRACELLULAR SPACE; HUMAN; HYPERALDOSTERONISM; HYPERKALEMIA; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; SIDE EFFECT;

ALDOSTERONE; ANIMALS; DIABETES COMPLICATIONS; HUMANS; HYPERALDOSTERONISM; KIDNEY; KIDNEY FAILURE, CHRONIC; RECEPTORS, MINERALOCORTICOID;

EID: 84856037918     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000334161     Document Type: Conference Paper

References (41)

1. Bomback AS, Klemmer PJ: The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007; 3: 486-492.
2. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.
3. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Klei-man J, Gatlin M: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309-1321.
4. Oliver WJ, Cohen EL, Neel JV: Blood pressure, sodium intake, and sodium related hormones in the Yanomamo Indians, a 'no-salt' culture. Circulation 1975; 52:146-151.
5. Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, Krakoff LR, Bard RH, Buhler FR: Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972; 286: 441-449.
6. Bomback AS, Kshirsagar AV, Ferris ME, Klemmer PJ: Disordered aldosterone-vol-ume relationship in end-stage kidney disease. J Renin Angiotensin Aldosterone Syst 2009; 10:230-236.
7. Schrier RW, Masoumi A, Elhassan E: Aldo-sterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome. Clin J Am Soc Nephrol 2010; 5: 1132-1140.
8. Sato A, Saruta T: Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status. Hypertens Res 2004; 27: 303-310.
9. Shibata S, Nagase M, Yoshida S, Kawarazaki W, Kurihara H, Tanaka H, Miyoshi J, Takai Y, Fujita T: Modification of mineralocorti-coid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med 2008; 14: 1370-1376.
10. Liu WF, Nelson CM, Tan JL, Chen CS: Cad-herins, RhoA, and Rac1 are differentially required for stretch-mediated proliferation in endothelial versus smooth muscle cells. Circ Res 2007; 101:e44-e52.
11. Gros R, Ding Q, Sklar LA, Prossnitz EE, Ar-terburn JB, Chorazyczewski J, Feldman RD: GPR30 expression is required for the min-eralocorticoid receptor-independent rapid vascular effects of aldosterone. Hypertension 2011; 57: 442-451.
12. Nishiyama A, Yao L, Fan Y, Kyaw M, Kataoka N, Hashimoto K, Nagai Y, Nakamura E, Yoshizumi M, Shokoji T, Kimura S, Kiyomoto H, Tsujioka K, Kohno M, Tamaki T, Kajiya F, Abe Y: Involvement of aldosterone and min-eralocorticoid receptors in rat mesangial cell proliferation and deformability. Hypertension 2005; 45: 710-716.
13. Quinkler M, Zehnder D, Eardley KS, Lepenies J, Howie AJ, Hughes SV, Cockwell P, Hewison M, Stewart PM: Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria. Circulation 2005; 112: 1435-1443.
14. Greene EL, Kren S, Hostetter TH: Role of al-dosterone in the remnant kidney model in the rat. J Clin Invest 1996; 98:1063-1068.
15. Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ: Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 2008; 51: 199-211.
16. Krikken JA, Laverman GD, Navis G: Benefits of dietary sodium restriction in the management of chronic kidney disease. Curr Opin Nephrol Hy pertens 2009; 18: 531-538.
17. Vogt L, Waanders F, Boomsma F, De ZD, Navis G: Effects of dietary sodium and hydro-chlorothiazide on the antiproteinuric efficacy of losar tan. J Am Soc Nephrol 2008; 19: 999-1007.
18. Vasavada N, Agarwal R: Role of excess volume in the pathophysiology of hypertension in chronic kidney disease. Kidney Int 2003; 64:1772-1779.
19. Lifton RP, Gharavi AG, Geller DS: Molecular mechanisms of human hypertension. Cell 2001; 104: 545-556.
20. Hene RJ, Boer P, Koomans HA, Mees EJ: Plasma aldosterone concentrations in chronic renal disease. Kidney Int 1982; 21:98-101.
21. Gross E, Rothstein M, Dombek S, Juknis HI: Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients. Am J Kidney Dis 2005; 46:94-101.
22. Goodfriend TL, Calhoun DA: Resistant hypertension, obesity, sleep apnea, and aldo-sterone: theory and therapy. Hypertension 2004; 43: 518-524.
23. Doi M, Takahashi Y, Komatsu R, Yamazaki F, Yamada H, Haraguchi S, Emoto N, Okuno Y, Tsujimoto G, Kanematsu A, Ogawa O, Todo T, Tsutsui K, van der Horst GT, Oka-mu r a H: S a lt-sensit i ve hy p er t e n s ion i n c i rc a-dian clock-deficient Cry-null mice involves dysregulated adrenal Hsd3b6. Nat Med 2010; 16:67-74.
24. Visser FW, Krikken JA, Muntinga JH, Dierckx RA, Navis GJ: Rise in extracellular fluid volume during high sodium depends on BMI in healthy men. Obesity (Silver Spring) 2009; 17:1684-1688.
25. Funder JW: Why are mineralocorticoid receptors so nonselective? Curr Hypertens Rep 2007; 9: 112-116.
26. Eijkelkamp WB, Zhang Z, Remuzzi G, Par-ving HH, Cooper ME, Keane WF, Shahin-far S, Gleim GW, Weir MR, Brenner BM, De ZD: Albuminuria is a target for renopro-tective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (R ENA AL) trial. J Am Soc Nephrol 2007; 18: 1540-1546.
27. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF: Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009; 4:542-551.
28. Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD: Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 2009; 20: 2641-2650.
29. Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, Patni R, Beckerman B: Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006; 1:940-951.
30. Bianchi S, Bigazzi R, Campese VM: Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases. Am J Kidney Dis 2010; 55:671-681.
31. Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T: Effect of renin-angioten-sin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-con- verting enzyme inhibitor and angiotensin II receptor blocker. Hy pertens Res 2008; 31: 59-67.
32. Pisoni R, Acelajado MC, Cartmill FR, Dudenbostel T, Dell'italia LJ, Cofield SS, Oparil S, Calhoun DA: Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease. J Hum Hypertens 2011, E-pub ahead of print.
33. Schepkens H, Vanholder R, Billiouw JM, La-meire N: Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spirono-lactone: an analysis of 25 cases. Am J Med 2001; 110:438-441.
34. Khosla N, Kalaitzidis R, Bakris GL: Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol 2009; 30:418-424.
35. Matsumoto Y, Kageyama S, Yakushigawa T, Arihara K, Sugiyama T, Mori Y, Sugiyama H, Ohmura H, Sh io N: Long-term low-dose spi-ronolactone therapy is safe in oligoanuric he-modialysis patients. Cardiology 2009; 114: 32-38.
36. Taheri S, Mortazavi M, Shahidi S, Pour-moghadas A, Garakyaraghi M, Seirafian S, Eshaghian A, Ghassami M: Spironolactone in chronic hemodialysis patients improves cardiac function. Saudi J Kidney Dis Transpl 2009; 20: 392-397.
37. Bianchi S, Bigazzi R, Campese VM: Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006; 70:2116-2123.
38. Sato A, Funder JW, Saruta T: Involvement of aldosterone in left ventricular hypertrophy of patients with end-stage renal failure treated with hemodialysis. Am J Hypertens 1999; 12:867-873.
39. Raimann JG, Liu L, Zhu F, Thijssen S, Carter M, Bomback AS, Derebail VK, Klemmer PJ, Levin NW, Kotanko P: Changes in serum al-dosterone relate to reduction of extracellular volume in hemodialysis patients (abstract). ASN Renal Week, 2010.
40. Schjoedt KJ, Andersen S, Rossing P, Tarnow L, Parving HH: Aldosterone escape during blockade of the renin-angiotensin-aldoste-rone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 2004; 47: 1936-1939.
41. Volk MJ, Bromback AS, Klemmer PJ: Miner-alocorticoid receptor blockade in chronic k idney disease. Cu r r Hy p er t e n s Rep 2011; 13: 282-288